From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases.

@article{Malfitano2005FromCT,
  title={From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases.},
  author={Anna Maria Malfitano and Giuseppe Matarese and Maurizio Bifulco},
  journal={Current drug targets. CNS and neurological disorders},
  year={2005},
  volume={4 6},
  pages={667-75}
}
An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of multiple sclerosis, including spasticity and pain. Endogenous molecules with cannabinoid-like activity, such as the "endocannabinoids", have been shown to mimic the anti-inflammatory properties of cannabinoids through the cannabinoid receptors. Several studies suggest that cannabinoids and endocannabinoids may have a key role in the pathogenesis and therapy of multiple sclerosis. Indeed, they… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
From cannabis to endocannabinoids in multiple sclerosis : a paradigm of central nervous system autoimmune diseases .
From cannabis to endocannabinoids in multiple sclerosis : a paradigm of central nervous system autoimmune diseases .
From cannabis to endocannabinoids in multiple sclerosis : a paradigm of central nervous system autoimmune diseases .
From cannabis to endocannabinoids in multiple sclerosis : a paradigm of central nervous system autoimmune diseases .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
From cannabis to endocannabinoids in multiple sclerosis : a paradigm of central nervous system autoimmune diseases .
From cannabis to endocannabinoids in multiple sclerosis : a paradigm of central nervous system autoimmune diseases .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
In vivo studies using mice with experimental allergic encephalomyelitis , an animal model of multiple sclerosis , suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect , and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis .
An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of multiple sclerosis , including spasticity and pain .
An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of multiple sclerosis , including spasticity and pain .
From cannabis to endocannabinoids in multiple sclerosis : a paradigm of central nervous system autoimmune diseases .
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
Endogenous molecules with cannabinoid - like activity , such as the " endocannabinoids " , have been shown to mimic the anti - inflammatory properties of cannabinoids through the cannabinoid receptors .
All Topics